Recently, CEP192 has been recognized as a new gene involved in the advancement of non-alcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC) (Cai, Song & Yu, 2020). The gene discussed is CEP192; the disease is metabolic dysfunction-associated steatotic liver disease.